Publicaciones en las que colabora con José Pablo Berros (8)

2017

  1. Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours

    Journal of Translational Medicine, Vol. 15, Núm. 1

2015

  1. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

    Melanoma Research, Vol. 25, Núm. 6, pp. 486-495

2014

  1. Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC)

    Investigational New Drugs, Vol. 32, Núm. 2, pp. 377-381

2012

  1. Predictive factors for response to treatment in patients with advanced renal cell carcinoma

    Investigational New Drugs, Vol. 30, Núm. 6, pp. 2443-2449

  2. Prognostic factors in patients with advanced renal cell carcinoma

    Clinical Genitourinary Cancer, Vol. 10, Núm. 4, pp. 262-270

2011

  1. Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: A phase II study

    Investigational New Drugs, Vol. 29, Núm. 6, pp. 1459-1464

  2. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: A phase Ib study

    International Journal of Gynecological Cancer, Vol. 21, Núm. 3, pp. 478-485

2010

  1. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: Study based on experience at the Hospital Universitario Central de Asturias

    Clinical and Translational Oncology, Vol. 12, Núm. 8, pp. 562-567